"The Buzz on The Street: Stocks in the Headlines Look Now!": CLNV, INBS, VTAK

Getting your Trinity Audio player ready...

There are a fair number of stocks that have created a fair degree of buzz in the markets in recent days. Here is a look at three such stocks that you could consider tracking at this point.

Clean Vision Corporation (OTCQB: CLNV), a rising force in the sustainable green energy and clean technology domains, recently revealed a significant development on December 5. The company proudly announced the acquisition of a trademark for AquaH®, its proprietary clean hydrogen, as granted by the United States Patent and Trademark Office.

Utilizing cutting-edge technology, the company generates clean hydrogen by employing innovative methods that utilize waste plastic as the primary input. This approach aligns with Clean Vision’s overarching goal of producing carbon-neutral hydrogen from sustainable sources. Emphasizing this breakthrough, the company highlighted in its press release that AquaH® represents a significant stride in the clean energy solutions market. Moreover, it reinforces the company’s steadfast dedication to advancing the circular economy and various sustainable energy technologies.

Intelligent Bio Solutions Inc. (Nasdaq: INBS): The medical technology firm, Intelligent Bio Solutions, revealed on December 5 that P&O Ferries has implemented its innovative Intelligent Fingerprinting Drug Screening System for swift, non-intrusive drug and alcohol testing. This adoption is part of P&O Ferries’ comprehensive drug and alcohol testing policy. As a prominent player in the ferry and logistics sector, P&O Ferries operates extensively throughout Europe.

P&O Ferries plans to implement the system at three ferry ports in the United Kingdom, specifically in Hull and Dover, England, and Larne in Northern Ireland. Intelligent Bio Solutions will supply portable screening cartridges and DSR-Plus readers for the random testing of seafaring staff. It’s important to highlight that this system deployment not only contributes to maintaining a safer work environment for P&O but also offers a significantly more cost-effective method for drug testing.

Catheter Precision, Inc. (NYSE American: VTAK), a cutting-edge medical technology firm, revealed on December 5 that it had received an invitation to present at the Emerging Growth Conference scheduled for December 6, 2023. During the event, Catheter Precision will spotlight its groundbreaking non-invasive 3D mapping system, VIVO™, designed to assist physicians in pinpointing the source of ventricular arrhythmias before medical procedures while enhancing workflow efficiency and shortening procedure durations. This cost-effective and innovative remedy has obtained regulatory approval from the United States Food and Drug Administration (FDA) and is currently accessible for commercial use in Europe. The presentation was delivered by CEO David Jenkins, Click here to Watch Now!